<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04225884</url>
  </required_header>
  <id_info>
    <org_study_id>3129002</org_study_id>
    <nct_id>NCT04225884</nct_id>
  </id_info>
  <brief_title>Digital Therapeutics (DTx) for Pain: Pilot Study of a Virtual Reality Software for Chronic Pain</brief_title>
  <acronym>VIRPI</acronym>
  <official_title>DTx for Pain: Behavioural Revalidation in Augmented and Virtual Reality for Chronic Pain; and Exploratory Pilot Study of a Virtual Reality Software</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Orion Corporation, Orion Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Orion Corporation, Orion Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, randomised, double-blind, 3-arm parallel group comparison of 2 different virtual&#xD;
      reality softwares and standard care.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective, randomised, double-blind, 3-arm parallel group comparison of DTx for pain&#xD;
      (treatment A), control (treatment B) and an open standard care arm, over 6-8 weeks. An&#xD;
      optional adaptive, multi-objective, multi-purpose, extension is included. Study devices will&#xD;
      be delivered to the patient's home with instructions for use; patients will receive remote&#xD;
      technical support.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 4, 2020</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Self-report of disability, Oswestry</measure>
    <time_frame>From randomisation upto 6-8 weeks</time_frame>
    <description>Oswestry Disability Index (subjects with a score of ≤22 will be considered as responders), index 0%-100% (0=no disability, 100=maximum disability possible).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Self-report of disability; Pain Interference</measure>
    <time_frame>From randomisation upto 6-8 weeks</time_frame>
    <description>The Patient Reported Outcomes Information System (PROMIS) 6b - Pain Interference Scale, score 6-30 (6=pain not at all interfering patient's life, 30=maximum interfering to patient's life).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective report of disability, steps</measure>
    <time_frame>From randomisation upto 6-8 weeks</time_frame>
    <description>Average number of steps per day over one week, as assessed by wearable equipment, 0-maximum amount of steps (0=patient not taking steps at all, maximum disability; maximum number of steps=minimum disability).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fear of movement and re-injury</measure>
    <time_frame>From randomisation upto 6-8 weeks</time_frame>
    <description>Tampa Scale of Kinesiophobia (TSK), score 17-68 (17=negligible or no kinesiophobia,68=extreme fear of pain with movement).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain Behaviour, pain intensity</measure>
    <time_frame>From randomisation upto 6-8 weeks</time_frame>
    <description>Numerical Rating Scale, PROMIS 3a - Pain Intensity Scale, score 3-15 (3=no pain,15=very severe pain).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain Behaviour, pain medications</measure>
    <time_frame>From randomisation upto 6-8 weeks</time_frame>
    <description>Any changes in pain medication during the study period are reported as outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality of life, own experience</measure>
    <time_frame>From randomisation upto 6-8 weeks</time_frame>
    <description>EuroQol-5D-5L-scale: European Quality (EQ) of Life (l), 5-dimension-5-level-scale. a). Descriptive System, 5-dimension-5-level-scale, scores are converted to a value where 1 equals 'perfect health' and 0 equals 'dead'. b). Visual Analogue Score, score 0 to 100 where 100 is the best health you can imagine and 0 = the worst health you can imagine.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality of life, adverse events</measure>
    <time_frame>From randomisation upto 6-8 weeks</time_frame>
    <description>Adverse Event reporting, number of adverse events and their severity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality of life, change</measure>
    <time_frame>From randomisation upto 6-8 weeks</time_frame>
    <description>Patient Clinical Global Impression of Change (PGIC) results, score 1-7 (1=very much improved, 7=very much worse).</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Chronic Low Back Pain</condition>
  <arm_group>
    <arm_group_label>DTx for pain</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment A software</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Treatment B software</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard care</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Pain medication</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>DTx for pain software</intervention_name>
    <description>Software with active intervention</description>
    <arm_group_label>DTx for pain</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Control software</intervention_name>
    <description>Software without active intervention</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard care</intervention_name>
    <description>Pain medication</description>
    <arm_group_label>Standard care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Competent male or female adults (age ≥ 18 years).&#xD;
&#xD;
          -  Chronic low back pain&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  Finnish speaking&#xD;
&#xD;
          -  having a clear, flat surface of at least 2 x 2 m of size to interact with DTx for pain&#xD;
&#xD;
          -  Can stoop without severe pain&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of epilepsy, migraine, vertigo or psychosis&#xD;
&#xD;
          -  Confirmed diagnosis of cancer&#xD;
&#xD;
          -  Prone to strong motion sickness requiring treatment&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Physiotherapy based interventions contraindicated&#xD;
&#xD;
          -  Severe or acute structural pathologies (e.g. spondylitis, epidural abscess,&#xD;
             spondylolisthesis, acute herniated or ruptured disc, traumatic injury, or severe&#xD;
             spinal stenosis) that could be worsened by the intervention as assessed by the&#xD;
             principal investigator&#xD;
&#xD;
          -  Has received (in last 2 years) or is receiving formal psychotherapy from a&#xD;
             psychologist for pain or allied health care professional at the screening stage&#xD;
&#xD;
          -  Any other condition that would affect posture or balance, and&#xD;
&#xD;
          -  Prior participation in DTx for pain feasibility study or in any part of the current&#xD;
             study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Orion Pharma Clinical Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Orion Corporation, Orion Pharma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CPU Orion Pharma</name>
      <address>
        <city>Espoo</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>December 20, 2019</study_first_submitted>
  <study_first_submitted_qc>January 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 13, 2020</study_first_posted>
  <last_update_submitted>September 14, 2021</last_update_submitted>
  <last_update_submitted_qc>September 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Low Back Pain</mesh_term>
    <mesh_term>Chronic Pain</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

